ACE2 and COVID-19: Evidence suggests that type 2 airway inflammation, common in asthma, may lower susceptibility to COVID-19 due to reduced expression of ACE2 and TMPRSS2 receptors, with corticosteroids further decreasing their expression, potentially providing additional protection [41].